17β-p-toluoyloxy-androst-4-en-3-one | 122747-09-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17β-p-toluoyloxy-androst-4-en-3-one
• 英文别名: 17β-p-Toluoyloxy-androst-4-en-3-on；[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 4-methylbenzoate
• CAS: 122747-09-5
• 化学式: C₂₇H₃₄O₃
• 分子量: 406.565
• InChiKey: GVOJOCSWNUMRDS-ZLQWOROUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对氯甲苯 、 睾酮 在 吡啶 作用下， 生成 17β-p-toluoyloxy-androst-4-en-3-one
  参考文献：
  名称：

  Gould et al., Journal of the American Chemical Society, 1957, vol. 79, p. 4472,4474

  摘要：

  DOI：

文献信息

• Androstanes as androgen receptor modulators
  申请人：——

  公开号：US20040235808A1

  公开（公告）日：2004-11-25

  Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating a function of the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteopenia, osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, inflammatory arthritis and joint repair, alone or in combination with other active agents.

  本文所定义的结构式（I）的化合物被披露为在患者中以组织选择性的方式调节雄激素受体功能的方法中有用，以及在患者中激活雄激素受体功能的方法，特别是在男性患者的前列腺或女性患者的子宫中阻止雄激素受体功能并在骨骼和/或肌肉组织中激活雄激素受体功能的方法。这些化合物在治疗由雄激素缺乏引起或可以通过雄激素治疗改善的疾病中有用，包括骨质疏松症、骨质疏松、牙周病、骨折、骨重建手术后的骨损伤、肌肉萎缩、虚弱、老化皮肤、男性性腺功能减退、女性性功能障碍、绝经后妇女的症状、动脉硬化、高胆固醇血症、高脂血症、再生障碍性贫血和其他造血系统疾病、胰腺癌、肾癌、前列腺癌、炎性关节炎和关节修复，单独或与其他活性药物联合使用。
• ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS
  申请人：Merck & Co., Inc.

  公开号：EP1429779A2

  公开（公告）日：2004-06-23
• [EN] ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS<br/>[FR] ANDROSTANES TENANT LIEU DE MODULATEURS DE RECEPTEUR D'ANDROGENE
  申请人：MERCK & CO INC

  公开号：WO2003026568A2

  公开（公告）日：2003-04-03

  Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating a function of the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteopenia, osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, inflammatory arthritis and joint repair, alone or in combination with other active agents.